# Title
Veterinary Drug Evaluation Fees Regulations


# ID
SOR-96-143

# URL
http://laws-lois.justice.gc.ca/eng/regulations/SOR-96-143/FullText.html


# Summary
Every person who includes, in a supplement to a new drug submission referred to in section C.08.003 of the  Food and Drug Regulations , one or more components set out in column I of an item of Schedule II shall pay the applicable fee set out in column II of that item for the screening and examination of each component.
Every person who includes, in a preclinical new drug submission referred to in section C.08.005 of the  Food and Drug Regulations , one or more components set out in column I of an item of Schedule V shall pay the applicable fee set out in column II of that item for the screening and examination of each component.
(Section 5) NEW DRUG SUBMISSION Column I Column II Item Component Fee 1 Efficacy and safety data (in the intended species) to support a single route of administration, dosage form and indication in one animal species.
(Section 9) PRECLINICAL NEW DRUG SUBMISSION Column I Column II Item Component Fee 1 Efficacy and safety data (in the intended species) and protocol to support the conduct of clinical studies relative to a single dosage form, route of administration and indication in one species.


# Tags
['components', 'drugs', 'sections', 'fees', 'regulations', 'references', 'applicable', 'chemistry', 'animals', 'species', 'study', 'shall', 'submission', 'dosage', 'forms']


# Inconsistent Words
"[('application', 'apply'), ('apply', 'required'), ('containing', 'includes'), ('ends', 'follows'), ('evaluated', 'examined')]"


# Overlapping US Regulations
File Name: CFR-2018-title21-vol5, Reg (Part) Id: Pt. 314, URL:https://www.govinfo.gov/content/pkg/CFR-2018-title21-vol5/xml/CFR-2018-title21-vol5.xml
,Title's Name: Food and Drugs, Part's Name: PART 314—APPLICATIONS FOR FDA APPROVAL TO MARKET A NEW DRUG

File Name: CFR-2018-title21-vol6, Reg (Part) Id: Pt. 514, URL:https://www.govinfo.gov/content/pkg/CFR-2018-title21-vol6/xml/CFR-2018-title21-vol6.xml
,Title's Name: Food and Drugs, Part's Name: PART 514—NEW ANIMAL DRUG APPLICATIONS

File Name: CFR-2018-title21-vol7, Reg (Part) Id: Pt. 601, URL:https://www.govinfo.gov/content/pkg/CFR-2018-title21-vol7/xml/CFR-2018-title21-vol7.xml
,Title's Name: Food and Drugs, Part's Name: PART 601—LICENSING

File Name: CFR-2018-title21-vol5, Reg (Part) Id: Pt. 316, URL:https://www.govinfo.gov/content/pkg/CFR-2018-title21-vol5/xml/CFR-2018-title21-vol5.xml
,Title's Name: Food and Drugs, Part's Name: PART 316—ORPHAN DRUGS

File Name: CFR-2018-title21-vol6, Reg (Part) Id: Pt. 516, URL:https://www.govinfo.gov/content/pkg/CFR-2018-title21-vol6/xml/CFR-2018-title21-vol6.xml
,Title's Name: Food and Drugs, Part's Name: PART 516—NEW ANIMAL DRUGS FOR MINOR USE AND MINOR SPECIES




# NAICS Code
## Level 2 Codes
Code: 213, Title:Support activities for mining, and oil and gas extraction

Code: 335, Title:Electrical equipment, appliance and component manufacturing

Code: 115, Title:Support activities for agriculture and forestry




## Level 3 Codes
Code: 1112, Title:Vegetable and melon farming

Code: 3117, Title:Seafood product preparation and packaging

Code: 3322, Title:Cutlery and hand tool manufacturing







# Structured Analysis Summary
| Type        | Values                                                                                                                                                   |
|:------------|:---------------------------------------------------------------------------------------------------------------------------------------------------------|
| Money       | [(1000.0, 'USD'), (4840.0, 'USD'), (50.0, 'USD'), (2900.0, 'USD'), (10000.0, 'USD'), (720.0, 'USD'), (12590.0, 'USD'), (960.0, 'USD'), (15980.0, 'USD')] |
| Constraints | ['within', 'greater of', 'less than', 'lesser of', 'more than', 'before', 'after', 'maximum']                                                            |
| Duration    | ['60.0 day', '3 year']                                                                                                                                   |
| Condition   | ['if', 'where']                                                                                                                                          |
| Entities    | ['New Drug Submission', 'Council', 'Submission', 'Canadian', 'Canada', 'New', 'Application', 'Schedule II']                                              |
| Date        | ['1995-03-31', '2018-05-07', '1996-04-01', '1996-03-31', '1995-04-01']                                                                                   |


# Structured Analysis With Context
 


## Money
| Money            | Context                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|:-----------------|:---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (10000.0, 'USD') | Where the sum of the fees for components included in a submission, supplement or application is $10,000 or less, the fee for each component is payable at the time that the submission, supplement or application is filed.                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| (10000.0, 'USD') | Where the sum of the fees for components included in a submission, supplement or application is more than $10,000, the fee for each component is payable as follows: 10% of the fee for the component at the time that the submission, supplement or application is filed; 40% of the fee for the component on receipt of a notice from the Minister or Director stating that the submission, supplement or application has been accepted for examination; and 50% of the fee for the component on receipt of a notice from the Minister or Director stating that the examination of the component has been completed.                                                           |
| (10000.0, 'USD') | Where the sum of the fees for components included in a submission, supplement or application is $10,000 or less, the fee for each component is payable on receipt of a notice from the Minister or Director stating that the submission, supplement or application has been screened.                                                                                                                                                                                                                                                                                                                                                                                            |
| (10000.0, 'USD') | Where the sum of the fees for components included in a submission, supplement or application is more than $10,000, the fee for each component is payable as follows: 10% of the fee for the component on receipt of a notice from the Minister or Director stating that the submission, supplement or application has been screened; 40% of the fee for the component on receipt of a notice from the Minister or Director stating that the submission, supplement or application has been accepted for examination; and 50% of the fee for the component on receipt of a notice from the Minister or Director stating that the examination of the component has been completed. |
| (10000.0, 'USD') | Where the sum of the fees for components that are included in a submission, supplement or application and that are not yet under examination is $10,000 or less, the fee for each such component is payable on the later of April 1, 1996, and the date of receipt of a notice from the Minister or Director stating that the submission, supplement or application has been screened and accepted for examination.                                                                                                                                                                                                                                                              |
| (10000.0, 'USD') | Where the sum of the fees for components that are included in a submission, supplement or application and that are not yet under examination is more than $10,000, the fee for each such component is payable as follows: 50% of the fee for the component on the later of April 1, 1996, and the date of receipt of a notice from the Minister or Director stating that the submission, supplement or application has been screened and accepted for examination; and 50% of the fee for the component on receipt of a notice from the Minister or Director stating that the examination of the component has been completed.                                                   |
| (1000.0, 'USD')  | The Minister or Director shall grant an application made under subsection (2) where the Minister or Director has reasonable grounds to believe that, during the fee verification period, the applicant’s revenue from sales in Canada of the drug to which the submission, supplement or application relates will be less than 10 times the sum of the applicable fees calculated in accordance with sections 5 to 7, 14 and 15; and the applicant submits with the application a fee for processing the application in the amount of $1,000.                                                                                                                                    |
| (15980.0, 'USD') | $15,980 2 Efficacy and safety data (in the intended species) to support a single route of administration and dosage form for an antiparasitic drug in one non-food animal species.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| (12590.0, 'USD') | $12,590 2 Efficacy and safety data (in the intended species) to support a single route of administration and dosage form for an antiparasitic drug in one non-food animal species.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| (2900.0, 'USD')  | $2,900 3 For food-producing animals, residue depletion studies to confirm that the withdrawal period(s) for each species falls within the conditions of use for the Canadian reference product.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| (720.0, 'USD')   | $720 2 Published references or other data.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| (4840.0, 'USD')  | $4,840 2 Efficacy data and protocol to support the conduct of clinical studies relative to a single route of administration and indication with a dosage form for which a notice of compliance has been issued for use in the species to be treated.                                                                                                                                                                                                                                                                                                                                                                                                                             |
| (960.0, 'USD')   | $960 2 Information and material to support the issuance of an experimental studies certificate whose protocol is the same as that for a previously authorized experimental studies certificate for a drug to be administered to a non-food-producing animal.                                                                                                                                                                                                                                                                                                                                                                                                                     |
| (50.0, 'USD')    | $50 2 Information and material to support the sale of a drug to be used in the emergency treatment of a food-producing animal.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |


## Constraints
| Constraints   | Context                                                                                                         |
|:--------------|:----------------------------------------------------------------------------------------------------------------|
| before        | sections 5 to 11 was filed on or before  March 31, 1995.                                                        |
| after         | Application Filed on or After April 1, 1996. after                                                              |
| after         | 5 to 11 that is filed on or after  April 1, 1996.                                                               |
| more than     | included in a submission, supplement or application is more than $10,000, the fee for each component is payable |
| before        | Supplement or Application Filed Before April 1, 1996. before                                                    |
| more than     | included in a submission, supplement or application is more than $10,000, the fee for each component is payable |
| more than     | and that are not yet under examination is more than $10,000, the fee for each such component is                 |
| less than     | under examination is where 25% or more but less than 50% of the component remains to be examined,               |
| less than     | under examination is where 25% or more but less than 50% of the component remains to be examined,               |
| after         | first sold in Canada and ending three years after  that date.                                                   |
| less than     | the submission, supplement or application relates will be less than 10 times the sum of the applicable fees     |
| lesser of     | in the submission, supplement or application is the lesser of the sum of the applicable fees calculated in      |
| greater of    | 5 to 7, 14 and 15, and the greater of 10% of the applicant’s anticipated revenue from sales                     |
| after         | the balance, if any, is payable 60 days after the day on which the fee verification period                      |
| maximum       | intake with a safety factor of 1,000, a maximum residue limit and a withdrawal period for a                     |
| less than     | acceptable daily intake with a safety factor of less than 1,000, a maximum residue limit and a withdrawal       |
| maximum       | a safety factor of less than 1,000, a maximum residue limit and a withdrawal period for a                       |
| maximum       | metabolism and residue depletion studies to establish a maximum residue limit and a withdrawal period for a     |
| within        | A medicinal ingredient that has been evaluated,  within the last three years, in another submission to          |
| maximum       | metabolism and residue depletion studies to establish a maximum residue limit and a withdrawal period for a     |
| maximum       | a change of an established acceptable daily intake, maximum  residue limit and withdrawal period.               |
| within        | that the withdrawal period(s) for each species falls within the conditions of use for the Canadian reference    |
| within        | 2 A medicinal ingredient that has been evaluated,  within the last three years, in another submission to        |
| maximum       | to establish a temporary acceptable daily intake, a maximum residue limit and a withdrawal period for a         |
| maximum       | intake with a safety factor of 1,000, a maximum residue limit and a withdrawal period for a                     |
| less than     | acceptable daily intake with a safety factor of less than 1,000, a maximum residue limit and a withdrawal       |
| maximum       | a safety factor of less than 1,000, a maximum residue limit and a withdrawal period for a                       |
| within        | 2,420 A medicinal ingredient that has been evaluated,  within the last three years, in another submission to    |


## Duration
| Duration   | Context                                                                                                                                                                                                                                                                                                                                                                                |
|:-----------|:---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 3 year     | In this section,  fee verification period , in respect of a drug for which an application is made under this section, means the period beginning on the date that the drug is first sold in Canada and ending three years after that date.                                                                                                                                             |
| 60.0 day   | The fee calculated in accordance with subsection (4) is payable as follows: 10% of the applicant’s anticipated revenue from sales of the drug in Canada during the fee verification period is payable at the times and in the manner set out in sections 12 to 15, as applicable; and the balance, if any, is payable 60 days after the day on which the fee verification period ends. |
| 3 year     | A medicinal ingredient that has been evaluated, within the last three years, in another submission to which reference is made is not required to be re-evaluated.                                                                                                                                                                                                                      |
| 3 year     | 2 A medicinal ingredient that has been evaluated, within the last three years, in another submission to which reference is made is not required to be re-evaluated.                                                                                                                                                                                                                    |
| 3 year     | 2,420 A medicinal ingredient that has been evaluated, within the last three years, in another submission to which reference is made is not required to be re-evaluated.                                                                                                                                                                                                                |


## Condition
| Condition   | Context                                                                                                                        |
|:------------|:-------------------------------------------------------------------------------------------------------------------------------|
| where       | to in any of sections 5 to 11 where it was filed during the period beginning on                                                |
| where       | to in any of sections 5 to 11 where it was filed during the period beginning on                                                |
| where       | to in any of sections 5 to 11 where the submission, supplement or application was filed during                                 |
| where       | application and that is still under examination is where 25% or more but less than 50% of                                      |
| where       | application and that is still under examination is where 25% or more but less than 50% of                                      |
| where       | application and that is still under examination is where 25% or more but less than 50% of                                      |
| where       | shall grant an application made under subsection (2) where the Minister or Director has reasonable grounds to                  |
| where       | Notwithstanding sections 5 to 7, 14 and 15,  where the Minister or Director grants an application made                         |
| if          | the drug in Canada during the fee ver if ication period is payable at the times and                                            |
| where       | This item applies only  where a new drug submission does not include any                                                       |
| if          | of food-producing animals, residue depletion studies to determine if  an extension to existing withdrawal periods is required. |
| where       | This item applies only  where a supplement to a new drug submission does                                                       |
| where       | This item applies only  where an abbreviated new drug submission or a supplement                                               |
| if          | submission of labelling material for a second review, if  required.                                                            |
| where       | 1 1 250 This item applies only  where a DIN application does not include either of                                             |


## Entities
| Entities            | Context                                                                                                           |
|:--------------------|:------------------------------------------------------------------------------------------------------------------|
| Canada              | on Behalf of Her Majesty in Right of Canada .                                                                     |
| Council             | 1996-295  His Excellency the Governor General in  Council , on the recommendation of the Minister of              |
| Canada              | on behalf of Her Majesty in right of Canada  .                                                                    |
| Application         | Application .                                                                                                     |
| New                 | New  Drug Submission.                                                                                             |
| New Drug Submission | Supplement to a  New Drug Submission .                                                                            |
| Submission          | Submission , Supplement or Application Filed on or After                                                          |
| Submission          | Submission , Supplement or Application Filed Before April 1,                                                      |
| Canada              | date that the drug is first sold in Canada  and ending three years after that date.                               |
| Canada              | verification period, the applicant’s revenue from sales in Canada of the drug to which the submission, supplement |
| Canada              | anticipated revenue from sales of the drug in Canada during the fee verification period, and 10% of               |
| Canada              | anticipated revenue from sales of the drug in Canada during the fee verification period, and 10% of               |
| Canada              | anticipated revenue from sales of the drug in Canada during the fee verification period is payable at             |
| Schedule II         | Component Fee 1 Any applicable component listed in Schedule II .                                                  |
| Canadian            | falls within the conditions of use for the Canadian  reference product.                                           |


## Date
| Date       | Context                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|:-----------|:-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 1995-03-31 | These Regulations do not apply in respect of a drug for veterinary use for which a submission, supplement or application referred to in any of sections 5 to 11 was filed on or before March 31, 1995.                                                                                                                                                                                                                                                                                                                                                                                                                         |
| 1996-04-01 | Submission, Supplement or Application Filed on or After April 1, 1996.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| 1996-04-01 | This section applies in respect of a submission, supplement or application referred to in any of sections 5 to 11 that is filed on or after April 1, 1996.                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| 1996-04-01 | Submission, Supplement or Application Filed Before April 1, 1996.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| 1995-04-01 | This section applies in respect of a submission, supplement or application referred to in any of sections 5 to 11 where it was filed during the period beginning on April 1, 1995 and ending on March 31, 1996; and as of April 1, 1996, the screening of the submission, supplement or application has not begun.                                                                                                                                                                                                                                                                                                             |
| 1996-03-31 | This section applies in respect of a submission, supplement or application referred to in any of sections 5 to 11 where it was filed during the period beginning on April 1, 1995 and ending on March 31, 1996; and as of April 1, 1996, the screening of the submission, supplement or application has not begun.                                                                                                                                                                                                                                                                                                             |
| 1996-04-01 | This section applies in respect of a submission, supplement or application referred to in any of sections 5 to 11 where it was filed during the period beginning on April 1, 1995 and ending on March 31, 1996; and as of April 1, 1996, the screening of the submission, supplement or application has not begun.                                                                                                                                                                                                                                                                                                             |
| 1995-04-01 | This section applies in respect of a submission, supplement or application referred to in any of sections 5 to 11 where it was filed during the period beginning on April 1, 1995 and ending on March 31, 1996; and as of April 1, 1996, the screening of the submission, supplement or application has begun but is not completed, or the submission, supplement or application has been screened and accepted for examination but one or more of the components included in it are not yet under examination.                                                                                                                |
| 1996-03-31 | This section applies in respect of a submission, supplement or application referred to in any of sections 5 to 11 where it was filed during the period beginning on April 1, 1995 and ending on March 31, 1996; and as of April 1, 1996, the screening of the submission, supplement or application has begun but is not completed, or the submission, supplement or application has been screened and accepted for examination but one or more of the components included in it are not yet under examination.                                                                                                                |
| 1996-04-01 | This section applies in respect of a submission, supplement or application referred to in any of sections 5 to 11 where it was filed during the period beginning on April 1, 1995 and ending on March 31, 1996; and as of April 1, 1996, the screening of the submission, supplement or application has begun but is not completed, or the submission, supplement or application has been screened and accepted for examination but one or more of the components included in it are not yet under examination.                                                                                                                |
| 1996-04-01 | Notwithstanding sections 5 to 11, the fee payable for the examination of each component not yet under examination as of April 1, 1996 is 90% of the applicable fee set out in the relevant schedule.                                                                                                                                                                                                                                                                                                                                                                                                                           |
| 1996-04-01 | Where the sum of the fees for components that are included in a submission, supplement or application and that are not yet under examination is $10,000 or less, the fee for each such component is payable on the later of April 1, 1996, and the date of receipt of a notice from the Minister or Director stating that the submission, supplement or application has been screened and accepted for examination.                                                                                                                                                                                                            |
| 1996-04-01 | Where the sum of the fees for components that are included in a submission, supplement or application and that are not yet under examination is more than $10,000, the fee for each such component is payable as follows: 50% of the fee for the component on the later of April 1, 1996, and the date of receipt of a notice from the Minister or Director stating that the submission, supplement or application has been screened and accepted for examination; and 50% of the fee for the component on receipt of a notice from the Minister or Director stating that the examination of the component has been completed. |
| 1995-04-01 | This section applies in respect of each component included in a submission, supplement or application referred to in any of sections 5 to 11 where the submission, supplement or application was filed during the period beginning on April 1, 1995 and ending on March 31, 1996; and as of April 1, 1996, the component is still under examination.                                                                                                                                                                                                                                                                           |
| 1996-03-31 | This section applies in respect of each component included in a submission, supplement or application referred to in any of sections 5 to 11 where the submission, supplement or application was filed during the period beginning on April 1, 1995 and ending on March 31, 1996; and as of April 1, 1996, the component is still under examination.                                                                                                                                                                                                                                                                           |
| 1996-04-01 | This section applies in respect of each component included in a submission, supplement or application referred to in any of sections 5 to 11 where the submission, supplement or application was filed during the period beginning on April 1, 1995 and ending on March 31, 1996; and as of April 1, 1996, the component is still under examination.                                                                                                                                                                                                                                                                           |
| 2018-05-07 | A person who files a submission, supplement or application referred to in any of sections 5 to 7 may apply to the Minister or Director, as the case may be, for a reduction in the fee payable for each component included in the submission, supplement or application.                                                                                                                                                                                                                                                                                                                                                       |
| 1996-04-01 | These Regulations come into force on April 1, 1996.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |


